1-17 of 17
dulaglutide
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study

Petter Bjornstad, Silva A. Arslanian, Tamara S. Hannon, Philip S. Zeitler, Jennie L. Francis, Alexandra M. Curtis, Ibrahim Turfanda, David A. Cox
Journal: Diabetes Care
Diabetes Care 2024;47(9):1617–1621
https://doi.org/10.2337/dc24-0322
Published: 02 July 2024
View article titled, Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study
Open the PDF for Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study in another window
Journal Articles

Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Bo Zhang, Zhifeng Cheng, Ji Chen, Xin Zhang, Dexue Liu, Hongwei Jiang, Guoqing Ma, Xiaoyun Wang, Shenglian Gan, Juan Sun, Ping Jin, Jianjun Yi, Bimin Shi, Jianhua Ma, Shandong Ye, Guixia Wang, Linong Ji, Xuejiang Gu, Ting Yu, Pei An, Huan Deng, Haoyu Li, Li Li, Qingyang Ma, Lei Qian, Wenying Yang
Journal: Diabetes Care
Diabetes Care 2024;47(1):160–168
https://doi.org/10.2337/dc23-1287
Published: 09 November 2023
View article titled, Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Open the PDF for Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in another window
Journal Articles

Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis

Fady T. Botros, Hertzel C. Gerstein, Raleigh Malik, Claudia Nicolay, Anastasia Hoover, Ibrahim Turfanda, Helen M. Colhoun, Jonathan E. Shaw
Journal: Diabetes Care
Diabetes Care 2023;46(8):1524–1530
https://doi.org/10.2337/dc23-0231
Published: 21 June 2023
View article titled, Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis
Open the PDF for Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis in another window
Journal Articles

Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis

Hertzel C. Gerstein, Shun-Fu Lee, Guillaume Paré, M. Angelyn Bethel, Helen M. Colhoun, Anastasia Hoover, Mark Lakshmanan, Yanzhu Lin, Valentina Pirro, Hui-Rong Qian, Giacomo Ruotolo, Lars Ryden, Jonathan M. Wilson, Kevin L. Duffin
Journal: Diabetes Care
Diabetes Care 2023;46(5):1046–1051
https://doi.org/10.2337/dc22-2397
Published: 10 March 2023
View article titled, Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis
Open the PDF for Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis in another window
Journal Articles

Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis

Giulia Ferrannini, Linda G. Mellbin, Faith Kirabo, Chinthanie Ramasundarahettige, Hertzel C. Gerstein, Lars Rydén
Journal: Diabetes Care
Diabetes Care 2022;45(10):e146–e147
https://doi.org/10.2337/dc22-0903
Published: 30 August 2022
View article titled, Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis
Open the PDF for Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis in another window
Journal Articles

HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial

Anita Y.M. Kwan, Hertzel C. Gerstein, Jan Basile, Denis Xavier, Juan M. Maldonado, Sohini Raha, Manige Konig
Journal: Diabetes Care
Diabetes Care 2022;45(3):547–554
https://doi.org/10.2337/dc21-1160
Published: 18 January 2022
View article titled, HbA<sub>1c</sub> Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
Open the PDF for HbA<sub>1c</sub> Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial in another window
Journal Articles

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

Juan P. Frias, Enzo Bonora, Luis Nevarez Ruiz, Ying G. Li, Zhuoxin Yu, Zvonko Milicevic, Raleigh Malik, M. Angelyn Bethel, David A. Cox
Journal: Diabetes Care
Diabetes Care 2021;44(3):765–773
https://doi.org/10.2337/dc20-1473
Published: 04 January 2021
View article titled, Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
Open the PDF for Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11) in another window
Journal Articles

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

Mark L. Hartman, Arun J. Sanyal, Rohit Loomba, Jonathan M. Wilson, Amir Nikooienejad, Ross Bray, Chrisanthi A. Karanikas, Kevin L. Duffin, Deborah A. Robins, Axel Haupt
Journal: Diabetes Care
Diabetes Care 2020;43(6):1352–1355
https://doi.org/10.2337/dc19-1892
Published: 14 April 2020
View article titled, Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Open the PDF for Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in another window
Journal Articles

Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013–2018

Chintan V. Dave, Sebastian Schneeweiss, Deborah J. Wexler, Gregory Brill, Elisabetta Patorno
Journal: Diabetes Care
Diabetes Care 2020;43(4):921–924
https://doi.org/10.2337/dc19-1943
Published: 10 February 2020
View article titled, Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013–2018
Open the PDF for Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013–2018 in another window
Includes: Supplementary data
Journal Articles

Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide

Michael A. Nauck, Jean-Louis Frossard, Jamie S. Barkin, Greg Anglin, Ingrid E. Hensley, Kristine D. Harper, Zvonko Milicevic
Journal: Diabetes Care
Diabetes Care 2017;40(5):647–654
https://doi.org/10.2337/dc16-0984
Published: 10 March 2017
View article titled, Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide
Open the PDF for Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)

Francesco Giorgino, Marian Benroubi, Jui-Hung Sun, Alan G. Zimmermann, Valeria Pechtner
Journal: Diabetes Care
Diabetes Care 2015;38(12):2241–2249
https://doi.org/10.2337/dc14-1625
Published: 18 June 2015
View article titled, Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
Open the PDF for Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2) in another window
Includes: Supplementary data
Journal Articles

Erratum. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37: 2159–2167

Carol Wysham, Thomas Blevins, Richard Arakaki, Gildred Colon, Pedro Garcia, Charles Atisso, Debra Kuhstoss, Mark Lakshmanan
Journal: Diabetes Care
Diabetes Care 2015;38(7):1393–1394
https://doi.org/10.2337/dc15-er07b
Published: 11 June 2015
View article titled, Erratum. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37: 2159–2167
Open the PDF for Erratum. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37: 2159–2167 in another window
Journal Articles

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care 2014;37: 2149–2158

Michael Nauck, Ruth S. Weinstock, Guillermo E. Umpierrez, Bruno Guerci, Zachary Skrivanek, Zvonko Milicevic
Journal: Diabetes Care
Diabetes Care 2015;38(3):538
https://doi.org/10.2337/dc15-er03
Published: 12 February 2015
View article titled, Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care 2014;37: 2149–2158
Open the PDF for Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care 2014;37: 2149–2158 in another window
Journal Articles

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37: 2159–2167

Carol Wysham, Thomas Blevins, Richard Arakaki, Gildred Colon, Pedro Garcia, Charles Atisso, Debra Kuhstoss, Mark Lakshmanan
Journal: Diabetes Care
Diabetes Care 2014;37(10):2895
https://doi.org/10.2337/dc14-er10
Published: 10 September 2014
View article titled, Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37: 2159–2167
Open the PDF for Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37: 2159–2167 in another window
Journal Articles

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

Michael Nauck, Ruth S. Weinstock, Guillermo E. Umpierrez, Bruno Guerci, Zachary Skrivanek, Zvonko Milicevic
Journal: Diabetes Care
Diabetes Care 2014;37(8):2149–2158
https://doi.org/10.2337/dc13-2761
Published: 12 July 2014
View article titled, Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
Open the PDF for Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5) in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

Carol Wysham, Thomas Blevins, Richard Arakaki, Gildred Colon, Pedro Garcia, Charles Atisso, Debra Kuhstoss, Mark Lakshmanan
Journal: Diabetes Care
Diabetes Care 2014;37(8):2159–2167
https://doi.org/10.2337/dc13-2760
Published: 12 July 2014
View article titled, Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
Open the PDF for Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1) in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

Guillermo Umpierrez, Santiago Tofé Povedano, Federico Pérez Manghi, Linda Shurzinske, Valeria Pechtner
Journal: Diabetes Care
Diabetes Care 2014;37(8):2168–2176
https://doi.org/10.2337/dc13-2759
Published: 12 July 2014
View article titled, Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
Open the PDF for Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3) in another window
Includes: Supplementary data